|
Market Closed -
Nasdaq
05:00:00 14/11/2026 HKT
|
5-day change | 1st Jan Change | ||
| 253.40 USD | +1.17% |
|
+2.03% | +43.99% |
| 11-13 | Eisai, Biogen Launch Subcutaneous LEQEMBI Pen in Japan | MT |
| 11-09 | UCB And Biogen Announce Clinical Profile Data For Dapirolizumab Pegol In Systemic Lupus Erythematosus | CI |
| Market Cap | 37.46B 33.94B 31.4B 28.33B 53.38B 3,532B 55.27B 377B 150B 1,887B 141B 138B 5,989B | P/E 2026 * |
51.2x | P/E 2027 * | 22.8x |
|---|---|---|---|---|---|
| Enterprise Value | 43.09B 39.05B 36.12B 32.59B 61.41B 4,063B 63.58B 434B 172B 2,170B 162B 158B 6,890B | EV / Sales 2026 * |
4.07x | EV / Sales 2027 * | 3.76x |
| Free-Float |
85.81% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| BIIB | Delayed | |
CBOE
| BIIB | Real-time | |
|
Tradegate
| IDP | Real-time | |
|
Boerse Muenchen
| IDP | Real-time | |
|
Mexican S.E.
| BIIB * | End-of-day quote | |
|
Xetra
| IDP | Delayed | |
|
Deutsche Boerse AG
| IDP | Delayed | |
|
London S.E.
| 0R1B | Delayed | |
|
Borsa Italiana
| 1BIIB | End-of-day quote | |
|
Kazakhstan S.E.
| BIIB_KZ | End-of-day quote | |
|
Swiss Exchange
| BIIB | Delayed | |
|
Wiener Boerse
| BIIB | End-of-day quote | |
|
Börse Stuttgart
| IDP | Delayed | |
|
Santiago S.E.
| BIIB | End-of-day quote | |
|
Santiago S.E.
| BIIBCL | End-of-day quote | |
|
Swiss Exchange
| BIIB | Delayed |
Last Transcript: Biogen Inc.
| 1 day | +1.17% | ||
| 1 week | +2.03% | ||
| Current month | -0.09% | ||
| 1 month | +10.70% | ||
| 3 months | +20.29% | ||
| 6 months | +23.89% | ||
| Current year | +43.99% |
| 1 week | 246.44 |  | 261 |
| 1 month | 231.04 | | 261 |
| Current year | 160.36 | | 261 |
| 1 year | 160.36 | | 261 |
| 3 years | 110.04 | | 268.3 |
| 5 years | 110.04 | | 319.76 |
| 10 years | 110.04 | | 468.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 14/11/2022 | |
Robin Kramer
DFI | Director of Finance/CFO | 60 | 01/03/2025 |
Daniel Quirk
CTO | Chief Tech/Sci/R&D Officer | - | 28/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Eric Rowinsky
BRD | Director/Board Member | 69 | 23/03/2010 |
Stephen Sherwin
BRD | Director/Board Member | 77 | 01/01/2010 |
William Hawkins
BRD | Director/Board Member | 72 | 19/06/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 30/10/26 | Exercice | Chief Technology Officer | 1,735 | 0.0012% | ||
| 2/10/26 | Exercice | Controller/Auditor | 62 | 0.0000% | ||
| 1/9/26 | Free | General Counsel | 7,405 | 0.0050% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.17% | +2.03% | +53.83% | +13.84% | 37.46B | |
| +1.26% | +6.61% | +41.12% | +135.59% | 1,286B | |
| +0.79% | +3.45% | +46.35% | +93.56% | 688B | |
| +0.20% | +1.28% | +27.01% | +112.80% | 521B | |
| -0.44% | +3.69% | +39.60% | +69.51% | 386B | |
| +0.55% | +0.70% | +59.00% | +44.20% | 364B | |
| -0.12% | +0.74% | +26.78% | +58.43% | 302B | |
| +0.37% | +0.37% | +3.62% | +36.44% | 287B | |
| -0.30% | +1.14% | +38.59% | +74.61% | 252B | |
| +0.08% | +0.71% | +34.25% | +124.32% | 208B | |
| Average | +0.36% | +2.07% | +37.02% | +76.33% | 433B | |
| Weighted average by Cap. | +0.54% | +3.25% | +37.77% | +95.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10.57B 9.58B 8.86B 8B 15.07B 997B 15.6B 106B 42.22B 533B 39.68B 38.84B 1,691B | 10.78B 9.77B 9.03B 8.15B 15.36B 1,016B 15.9B 109B 43.03B 543B 40.44B 39.58B 1,723B |
| Net income | 788M 714M 660M 596M 1.12B 74.3B 1.16B 7.93B 3.15B 39.69B 2.96B 2.89B 126B | 1.79B 1.62B 1.5B 1.35B 2.55B 168B 2.64B 17.99B 7.13B 89.98B 6.7B 6.56B 286B |
| Net Debt | 5.63B 5.11B 4.72B 4.26B 8.03B 531B 8.31B 56.73B 22.5B 284B 21.14B 20.7B 901B | 3.08B 2.79B 2.58B 2.33B 4.39B 291B 4.55B 31.02B 12.3B 155B 11.56B 11.32B 493B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/11/26 | US$253.40 | +1.17% | 1,028,943 |
| 12/11/26 | US$250.48 | -1.15% | 792,515 |
| 11/11/26 | US$253.40 | +0.06% | 1,115,452 |
| 10/11/26 | US$253.25 | -0.64% | 735,026 |
| 09/11/26 | US$254.87 | +2.63% | 1,143,244 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- BIIB Stock
Select your edition
All financial news and data tailored to specific country editions
